
Commentary|Articles|March 31, 2026
Rising Rates, Screening Gaps, and Emerging Therapeutic Targets in CRC: Your Key Clinical Questions Answered
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Nicole Canfora Lupo
Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.
Advertisement
Advertisement
During colorectal cancer (CRC) awareness month, OncLive® sat down with Jeremy Kortmansky, MD, to discuss frequently asked questions about the complexities of CRC management and the rising incidence of CRC in young adults. The following FAQ, adapted from the conversation, provides clinical insights into potential risk factors for CRC in young adults, gaps in screening and early symptom identification contributing to this phenomenon, and the evolving landscape of molecularly targeted therapies in the space.
Related to this article

Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Advertisement
Advertisement

